Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ALK |
Variant | C1156Y |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | ALK C1156Y lies within the protein kinase domain of the Alk protein (UniProt.org). C1156Y has been demonstrated to occur as a secondary drug resistance mutation in the context of ALK fusions (PMID: 21613408, PMID: 20979473, PMID: 27490033, PMID: 27045755), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Aug 2024). |
Associated Drug Resistance | Y |
Category Variants Paths |
ALK mutant ALK C1156Y |
Transcript | NM_004304.5 |
gDNA | chr2:g.29222392C>T |
cDNA | c.3467G>A |
Protein | p.C1156Y |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_004304.4 | chr2:g.29222392C>T | c.3467G>A | p.C1156Y | RefSeq | GRCh38/hg38 |
NM_004304 | chr2:g.29222392C>T | c.3467G>A | p.C1156Y | RefSeq | GRCh38/hg38 |
NM_004304.5 | chr2:g.29222392C>T | c.3467G>A | p.C1156Y | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK C1156Y | Advanced Solid Tumor | sensitive | Alectinib | Preclinical - Biochemical | Actionable | In a preclinical study, ALK C1156Y was sensitive to Alecensa (alectinib) in an in vitro enzyme assay (PMID: 21575866). | 21575866 |
ALK C1156Y | Advanced Solid Tumor | predicted - sensitive | TPX-0131 | Preclinical - Biochemical | Actionable | In a preclinical study, TPX-0131 inhibited kinase activity of ALK C1156Y in an in vitro assay (PMID: 34158340). | 34158340 |